Received Feb 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | IM / RA |
Pain in injection area; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis. In OCT-2023, the patient received the 1st dose of Shingrix (intramuscular, right arm). On an unknown date, an unknown time after receiving Shingrix, the patient experienced injection site pain (Verbatim: Pain in injection area). The outcome of the injection site pain was resolving. It was unknown if the reporter considered the injection site pain to be related to Shingrix. It was unknown if the company considered the injection site pain to be related to Shingrix. Additional Information: GSK Receipt Date: 08-JAN-2025 Patient was the reporter. Patient received her 1st Shingrix vaccine in October 2023 in the right arm and has had intense pain since receiving the vaccine. Patient stated she received the 2nd vaccine in January 2024 in the left arm and had not had any pain. Patient had reached out to her health professional and the pain was ongoing.